NYT opinion page features a quartet of commentaries on DCIS research

Last week, a major study on the risks of ductal carcinoma in situ (DCIS) was published in JAMA Oncology. The results spurred the New York Times editorial section to run not one, but four different commentaries on the results.

There were a number of interesting findings in the JAMA Oncology study, but the headline was that DCIS has potential for distant metastatic spread and can be lethal without the presence of an invasive breast cancer. Researchers also found that radiotherapy or mastectomy treatments to limit recurrence didn’t reduce breast-cancer specific mortality.

Four columnists took to the pages of the Times to reflect on the implications of the findings, including officials with the American Cancer Society and National Women’s Health Network, a University of Pennsylvania professor and a breast cancer patient who’s nearly completed treatment. Their thoughts on treatment for early cancer, patient anxiety and more can be found at the link below:

Evan Godt
Evan Godt, Writer

Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.